Carpenter v. Oscar Health, Inc.

CourtDistrict Court, S.D. New York
DecidedSeptember 27, 2022
Docket1:22-cv-03885
StatusUnknown

This text of Carpenter v. Oscar Health, Inc. (Carpenter v. Oscar Health, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Carpenter v. Oscar Health, Inc., (S.D.N.Y. 2022).

Opinion

UNITED STATES DISTRICT COURT luca SOUTHERN DISTRICT OF NEW YORK DOCUMENT CARPENTERmiyanon Een fpoce:___ LORIN CARPTENTER, Individually and on DATE FILED: 0270020 Behalf of All Others Similarly Situated, — □ Plainuit, 22-CV-03885 (ALC) (VF) -against- ORDER OSCAR HEALTH, INC. et al., Defendants.

VALERIE FIGUEREDO, United States Magistrate Judge: Plaintiff Lorin Carpenter commenced this action, on behalf of himself and all others similarly situated, against Oscar Health, Inc. (“Oscar”) and various other defendants alleging violations of Sections 11 and 15 of the Securities Act of 1933, 15 U.S.C. §§ 77k and 770, as amended by the Private Securities Litigation Reform Act of 1995, 15 U.S.C. § 78u-4 et seq. Initially, four movants sought appointment as lead plaintiff in this action. See ECF Nos. 14, 17, 21 & 25. Two of the four movants have since filed notices of non-opposition to the competing motions. See ECF Nos. 46, 48. The two remaining individual movants—Vicki Riley- Fischer and Robert Scott Heon—subsequently filed a Proposed Order, stipulating to their appointment as co-lead plaintiff and appointment of their respective counsel as co-lead counsel. See ECF No. 50. No member of the purported plaintiff class opposes the appointment of Fischer and Heon as co-lead plaintiff. For the reasons stated herein, the Court now appoints Heon and Fischer as Co-Lead Plaintiff and their respective attorneys are approved as Co-Lead Counsel.

BACKGROUND Oscar is a health-insurance company that claims to be the first such company “built around a full stack technology platform,” which will allow it “to continue to innovate like a technology company and not a traditional insurer.” Compl. ¶ 2, ECF No. 1. Plaintiff commenced this class-action suit on May 12, 2022, on behalf of investors who purchased or acquired Class A

common stock of Oscar pursuant to the registration statement and prospectus issued in connection with the company’s initial public offering (“IPO”) in March 2021. Id. ¶ 1. Plaintiff claims that the registration statement was materially false and misleading and omitted to state, among other things, that Oscar was experiencing growing COVID-19 testing and treatment costs, and that Oscar was on track to be negatively impacted by significant “Special Enrollment Period” membership growth. Id. ¶ 9. Following certain disclosures by the company between August 2021 and November 2021, Oscar’s share price declined to $12.47 on November 11, 2021—a more than 85% decline from the $39.00 per share price at the time of its IPO. Id. ¶¶ 4-8. The complaint asserts two causes of action. The first cause of action alleges a violation of

Section 11 of the Securities Act, 15 U.S.C. § 77k, against all defendants, for misrepresentations and omissions made in the company’s registration statement. Id. ¶¶ 63-71. And the second cause of action alleges a violation of Section 15 of the Securities Act, 15 U.S.C. § 77o, against only the individual defendants. Id. ¶¶ 72-76. Now before the Court is the unopposed motion for the appointment of Heon and Fischer as co-lead plaintiff and for appointment of their respective attorneys as co-lead counsel.1 “Even

1 Although no other purported plaintiff opposes Heon and Fischer’s appointment as co- lead plaintiff, Oscar responded to the pending motions on July 26, 2022. See ECF No. 52. Although Oscar “takes no position on the motions for appointment of lead plaintiff or lead counsel,” it contends that Heon and Fischer have not proffered the evidentiary showing required for the Court to determine that they can function effectively to manage the litigation. Id. at 1-2. when a motion to appoint lead plaintiff is unopposed, the Court must still consider the factors under the PSLRA to ensure that the movant is the most adequate plaintiff.” City of Warren Police & Fire Ret. Sys. v. Foot Locker, Inc., 325 F. Supp. 3d 310, 314 (E.D.N.Y. 2018); see also Springer v. Code Rebel Corp., No. 16-CV-3492, 2017 WL 838197, at *1 (S.D.N.Y. Mar. 2, 2017) (noting that although motion was “unopposed, the Court must still ensure that it is the

most adequate plaintiff under the PSLRA”). A Magistrate Judge may issue an order appointing lead plaintiff and approving lead counsel under Rule 72 of the Federal Rules of Civil Procedure. See City of Hollywood Police Officers Ret. Sys. v. Henry Schein, Inc., 2019 WL 13167890, at *1 n.1 (E.D.N.Y. Dec. 23, 2019) (collecting cases); Salim v. Mobile TeleSystems PJSC, 2019 WL 11095253, at *1 n. 2 (E.D.N.Y. Sept. 11, 2019). DISCUSSION The Private Securities Litigation Reform Act (“PSLRA”) establishes the procedure for the appointment of a lead plaintiff in class actions brought pursuant to the Securities Act. As an initial matter, the plaintiff who files the first action must publish notice to the class within twenty

(20) days of filing the action, informing class members of (1) the pendency of the action; (2) the claims asserted therein; (3) the purported class period; and (4) the right to move the court to be appointed as lead plaintiff within sixty days of the publication of the notice. See 15 U.S.C. § 78u–4(a)(3)(A)(I). Within sixty days after publication of the notice, any member or group of members of the proposed class may apply to the court to be appointed as lead plaintiff, whether or not they have previously filed a complaint in the action. See 15 U.S.C. § 78u–4(a)(3)(A)-(B).

As discussed, see infra p. 7-8, Heon and Fischer’s sworn declaration adequately demonstrates that they are both sophisticated investors who will work together cohesively to effectively pursue the claims on behalf of the class. Within ninety days after publication of notice, the PSLRA provides that the Court shall consider any motion made by a purported class member and shall appoint as lead plaintiff the “member or members of the purported plaintiff class that the court determines to be most capable of adequately representing the interest of class members.” 15 U.S.C. § 78u-4(a)(3)(B). Pursuant to the PSLRA, the court “adopt[s] a presumption that the most adequate plaintiff in any private

action . . . is the person or group of persons that”: (1) “has either filed the complaint or made a motion in response to a notice”; (2) “in the determination of the court, has the largest financial interest in the relief sought by the class”; and (3) “otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.” 15 U.S.C. § 78u–4(a)(3)(B)(iii)(I)(aa)-(cc).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Olsten Corp. Securities Litig.
3 F. Supp. 2d 286 (E.D. New York, 1998)
Khunt v. Alibaba Group Holding Ltd.
102 F. Supp. 3d 523 (S.D. New York, 2015)
City of Warren Police v. Foot Locker, Inc.
325 F. Supp. 3d 310 (E.D. New York, 2018)
In re eSpeed, Inc. Securities Litigation
232 F.R.D. 95 (S.D. New York, 2005)
In re Fuwei Films Securities Litigation
247 F.R.D. 432 (S.D. New York, 2008)
Foley v. Transocean Ltd.
272 F.R.D. 126 (S.D. New York, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Carpenter v. Oscar Health, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/carpenter-v-oscar-health-inc-nysd-2022.